Bronchial Asthma and COVID-19: Comorbidity Issues

Ovsyannikov, Evgeniy; Авдеев, С. Н.; Budnevsky, A. V.; Дробышева, Елена Сергеевна; Savushkina, I. A.

doi:10.21292/2075-1230-2021-99-9-6-14

Cited by 7 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В одном из первых исследований, в котором оце нивались 140 госпитализированных пациентов с COVID19 в китайской провинции Ухань, случа ев астмы не наблюдалось [36]. Другое многоцен тровое исследование с участием 476 пациентов Как предположили ученые из России, противо речивые данные о встречаемости бронхиальной астмы у больных COVID19 в различных исследо ваниях могут быть связаны с общими отличиями в распространенности сопутствующих заболева ний, в том числе астмы, в разных странах [40].…”

Section: Sarscov2 и бронхиальная астмаunclassified

“…БА имела место у 1,8% больных. Было сделано предположение, что, в отличие от сердечнососудистой патологии и сахарного диабета, хронические респираторные заболевания незначительно повышают риск раз вития тяжелой формы COVID19, требующей госпи тализации в отделения интенсивной терапии и ис кусственной вентиляции легких [40].…”

Section: Sarscov2 и бронхиальная астмаunclassified

“…Отечественные ученые, проведя в 2021 г. анализ опубликованных данных, пришли к вы воду, что клинические исходы у пациентов с COVID19 и ХОБЛ хуже, они чаще нуждаются в ис кусственной вентиляции легких, среди них выше летальность [40]. Особенностью тяжелой формы COVID19 является высокий уровень системного воспаления, так называемый цитокиновый шторм, а также развитие тромбоза и коагулопатии в со судах малого круга кровообращения -фактора, способствующего ухудшению уже существующей дыхательной недостаточности у пациентов с ХОБЛ.…”

Section: хобл и Sarscov2unclassified

See 2 more Smart Citations

Prevalence of Bronchial Asthma and COPD in Comorbidity with COVID-19

Svist,

Torchinsky,

Briko

et al. 2024

Epidemiology and Vaccinal Prevention

View full text Add to dashboard Cite

Relevance. As is known, the presence of some concomitant diseases may be directly related to the severe course of Coronavirus infection and high mortality among the sick. However, the question of the possible impact of bronchial asthma and COPD on outcomes and survival rates in patients with COVID-19 remains relevant. Aim. To evaluate, according to the literature, the prevalence of bronchial asthma and COPD in the general population and among COVID-19 patients in the Russian Federation and in the world, and to determine the degree of their influence on outcomes. Materials and methods. The results of 1080 previously conducted domestic and foreign studies were studied, from which 46 papers were selected that meet the inclusion criteria. Based on the data presented in the studies on the prevalence of bronchial asthma and COPD, the analysis of survival rates, mortality and severity of the consequences of COVID-19 in patients with these pathologies was carried out. Results and discussions. Patients with COPD often had a more severe course of COVID-19, as well as high mortality rates due to the rapid progression of the pulmonary process. Earlier it was reported that patients with bronchial asthma did not notice a negative effect of COVID-19, but the results of recent studies prove the opposite, and therefore further observations are required in this cohort of patients. Conclusion.

show abstract

Section: Sarscov2 и бронхиальная астмаunclassified

Section: хобл и Sarscov2unclassified

See 1 more Smart Citation

Prevalence of Bronchial Asthma and COPD in Comorbidity with COVID-19

Svist,

Torchinsky,

Briko

et al. 2024

Epidemiology and Vaccinal Prevention

View full text Add to dashboard Cite

show abstract

Inflammasome-Mediated Mechanisms Of Systemic Inflammation In COVID-19 And Asthma

Vitkina,

Lobova,

Bogomaz

et al. 2024

Russ Open Med J

View full text Add to dashboard Cite

The review examines the formation of inflammasome-mediated mechanisms of systemic inflammation in asthma after COVID-19. It provides insight into the clinical and pathophysiological relationship between asthma and COVID-19. The review summarizes information about the role of the NLRP3 inflammasome in the pathogenesis of asthma and describes in detail its manifestations in various asthma phenotypes. Emphasizing the significance of the inflammatory-mediated immune response during coronavirus infection in patients with bronchopulmonary pathology, the review outlines the consequences of hyperactivation of the NLRP3 pathway, leading to increased production of cytokines, the appearance of neutrophil and monocyte-derived traps, induction of pyroptosis and the development of complications.

show abstract

Some features of the coronavirus infection course in bronchial asthma patients

Kharitonov

Burkova

Салухов

et al. 2022

Bulletin of the Russian Military Medical Academy

View full text Add to dashboard Cite

The outbreak of a new coronavirus infection was officially recognized by the World Health Organization as a global pandemic since March 11, 2020. The pandemic is currently gradually receding, the number of patients is also steadily decreasing. However, these circumstances are not grounds to believe that the virus has been definitively and irrevocably defeated. For this reason, the world medical community is still concerned about the coronavirus impact on the course and outcome of various chronic bronchopulmonary diseases. Bronchial asthma has been recognized as one of the leading forms of human somatic pathology throughout the history of mankind and medicine. It is quite natural that the focus of the researchers' attention turned out to be questions about the SARS-CoV-2 virus impact on patients suffering from bronchial asthma, starting with the peculiarities of the course of combined pathology and ending with the peculiarities of therapy and subsequent rehabilitation. The issues of coronavirus infection and bronchial asthma pathogenesis were considered. The research data on some features of the development and course of a new coronavirus infection in patients with this profile were analyzed and summarized. The low coronavirus infection prevalence among patients with an allergic bronchial asthma form compared with other phenotypes is shown among such features, data on the effect of eosinophilia on the course of infection are presented, and the basic therapys positive effect using inhaled glucocorticosteroids and/or monoclonal antibodies (biological therapy) in severe asthma, is shown in the form of a protective effect that provides a lighter coronavirus infection course. The main features of patient management suffering from bronchial asthma in the conditions of a pandemic are the organization of stable medical control in online telemedicine once monthly, regular examinations in accordance with the severity of the course of the disease and the correction of basic therapy to achieve complete control over the course of asthma.

show abstract

Bronchial Asthma and COVID-19: Comorbidity Issues

Cited by 7 publications

References 57 publications

Prevalence of Bronchial Asthma and COPD in Comorbidity with COVID-19

Prevalence of Bronchial Asthma and COPD in Comorbidity with COVID-19

Inflammasome-Mediated Mechanisms Of Systemic Inflammation In COVID-19 And Asthma

Some features of the coronavirus infection course in bronchial asthma patients

Contact Info

Product

Resources

About